去纤维钠的作用功效

(Alias: defibrinoside) is a mixture of single-stranded deoxyoligonucleotide sodium salts produced by controlled depolymerization of porcine intestinal mucosal genomic DNA. Its mechanism of action is complex and has not yet been fully elucidated. In 2013, defibrotide sodium was approved for marketing in the EU for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal or pulmonary dysfunction after hematopoietic stem cell transplantation (HSCT).

Defibrotide sodium is not currently on the market in my country, and many patients are still relatively unfamiliar with this drug. Let’s briefly understand its effects.

Defibrotide sodium (defibrotide) is a new drug approved in the United States in 2016. It is also the first drug approved by the U.S. FDA to treat severe hepatic veno-occlusive disease. At the same time, the drug has also received "orphan drug" qualifications. Defibrotide sodium is an adenosine receptor agonist with multiple effects. It can act on the adenosine A1/A2 receptors of endothelial cells to produce a variety of downstream effects. These receptors are involved in the regulation of endothelial cells and the response of endothelial cells to injury. In recent years, multiple clinical research results have shown that defibrotide sodium is a safe and effective drug for preventing and treating VOD.

In clinical trials, patients who developed VOD after HSCT were treated with defibrinated sodium. The survival rate after 100 days for patients treated with defibrated sodium was 38% to 45%. However, data analysis found that HSCT patients who were expected to receive only supportive care or other drug intervention had a survival rate of only 21% to 31% after 100 days. The use of defibrinated sodium significantly increased the survival rate of patients.

(Defibrinoside) also has a certain therapeutic effect on multiple myeloma. It has achieved good results in the treatment of multiple myeloma and hepatic veno-occlusive disease caused by chemotherapy and stem cell transplantation, meeting the treatment needs of this rare and fatal disease.

Recommended related hot articles: /newsDetail/71708.html